News Highlights
The Drugs Controller General of India’s (DCGI) Subject Expert Committee recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
quadrivalent Human Papillomavirus Vaccine (qHPV)
- Developed by – Indigenously by Serum Institute
- The vaccine has been recommended for cervical cancer patients – those above 9 years to 26 years of age
Cervical Cancer
- It forms 16.5 per cent of the total cancer cases in Indian women and is the second most common type of cancer amongst women in the country after breast cancer.
- It is caused by the human papillomavirus (HPV), a virus that is generally transmitted through sexual contact.
Content Source : Economic Times